Evidence map›Paper›PMID 38235139›Full record

ArticleFrontiers in immunology2023

Alterations in leukocyte DNA methylome are associated to immunosuppression in severe clinical phenotypes of septic patients.

Jesús Beltrán-García, Germán Casabó-Vallés, Rebeca Osca-Verdegal, Paula Navarrete-López, María Rodriguez-Gimillo, Elena Nacher-Sendra, Carolina Ferrando-Sánchez, Eva García-López, Federico V Pallardó, Nieves Carbonell and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Jesús Beltrán-GarcíaCenter for Biomedical Network Research on Rare Diseases (CIBERER), Carlos III Health Institute, Valencia, Spain.
Germán Casabó-VallésDepartment of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.
Rebeca Osca-VerdegalCenter for Biomedical Network Research on Rare Diseases (CIBERER), Carlos III Health Institute, Valencia, Spain.
Paula Navarrete-LópezDepartment of Animal Reproduction, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA)-Centro Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
María Rodriguez-GimilloINCLIVA Biomedical Research Institute, Valencia, Spain.
Elena Nacher-SendraINCLIVA Biomedical Research Institute, Valencia, Spain.
Carolina Ferrando-SánchezINCLIVA Biomedical Research Institute, Valencia, Spain.
Eva García-LópezCenter for Biomedical Network Research on Rare Diseases (CIBERER), Carlos III Health Institute, Valencia, Spain.
Federico V PallardóCenter for Biomedical Network Research on Rare Diseases (CIBERER), Carlos III Health Institute, Valencia, Spain.
Nieves CarbonellINCLIVA Biomedical Research Institute, Valencia, Spain.
Salvador Mena-MolláINCLIVA Biomedical Research Institute, Valencia, Spain.
José Luis García-GiménezCenter for Biomedical Network Research on Rare Diseases (CIBERER), Carlos III Health Institute, Valencia, Spain.
Hospital Clínico Universitario de Valencia · ESCentre for Biomedical Network Research on Rare Diseases · ESINCLIVA Health Research Institute · ESUniversitat de València · ESInstituto de Salud Carlos III · ESInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria · ESParc Científic de la Universitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sepsis patients experience a complex interplay of host pro- and anti-inflammatory processes which compromise the clinical outcome. Despite considering the latest clinical and scientific research, our comprehension of the immunosuppressive events in septic episodes remains incomplete. Additionally, a lack of data exists regarding the role of epigenetics in modulating immunosuppression, subsequently impacting patient survival. Methods: To advance the current understanding of the mechanisms underlying immunosuppression, in this study we explored the dynamics of DNA methylation using the Infinium Methylation EPIC v1.0 BeadChip Kit in leukocytes from patients suffering from sepsis, septic shock, and critically ill patients as controls, within the first 24 h after admission in the Intensive Care Unit of a tertiary hospital. Results and discussion: Employing two distinct analysis approaches (DMRcate and mCSEA) in comparing septic shock and critically ill patients, we identified 1,256 differentially methylated regions (DMRs) intricately linked to critical immune system pathways. The examination of the top 100 differentially methylated positions (DMPs) between septic shock and critically ill patients facilitated a clear demarcation among the three patient groups. Notably, the top 6,657 DMPs exhibited associations with organ dysfunction and lactate levels. Among the individual genes displaying significant differential methylation, IL10, TREM1, IL1B, and TNFAIP8 emerged with the most pronounced methylation alterations across the diverse patient groups when subjected to DNA bisulfite pyrosequencing analysis. These findings underscore the dynamic nature of DNA methylation profiles, highlighting the most pronounced alterations in patients with septic shock, and revealing their close association with the disease.

Indexed as

SepsisShock, SepticCritical IllnessEpigenomeHumansImmunosuppression TherapyLeukocytesPhenotypeDNA methylationimmune systemimmunosuppressioninflammationsepsis

Identifiers

PMID38235139
PMCPMC10791922
OpenAlexW4390571224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.